Chemotherapy News and Research RSS Feed - Chemotherapy News and Research

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. [More]
Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
New approach to solve global challenges in food security, emerging diseases and biodiversity loss

New approach to solve global challenges in food security, emerging diseases and biodiversity loss

Solving global challenges in food security, emerging diseases and biodiversity loss requires evolutionary thinking, argues a new study published online in Science Express that was co-authored by Bruce Tabashnik of the University of Arizona College of Agriculture and Life Sciences. [More]
Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). [More]
Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma. [More]
Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
Aptose joins Beat AML research collaboration

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration. [More]
Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid. [More]
FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. [More]
Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show. [More]
Chemotherapy, radiotherapy have no negative effect on unborn babies

Chemotherapy, radiotherapy have no negative effect on unborn babies

Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown. [More]
Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain. [More]
Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. [More]
Imperial scientists map proteins affected by NMT enzyme, suggest potential way to treat cancer

Imperial scientists map proteins affected by NMT enzyme, suggest potential way to treat cancer

Imperial chemists have gained fresh insights into how a disease-causing enzyme makes changes to proteins and how it can be stopped. [More]
Allegheny Health Network, Highmark Health commemorate opening of Health + Wellness Pavilion in Wexford

Allegheny Health Network, Highmark Health commemorate opening of Health + Wellness Pavilion in Wexford

Officials and employees of Highmark Health and Allegheny Health Network today joined community leaders and public officials to celebrate the planned October 1 grand opening of the Network's new Health + Wellness Pavilion in Wexford. [More]
Access to potentially life-extending cancer drugs varies worldwide

Access to potentially life-extending cancer drugs varies worldwide

Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain. [More]
Lya Segall Ovarian Cancer Institute at Mercy opens in Maryland

Lya Segall Ovarian Cancer Institute at Mercy opens in Maryland

Mercy Medical Center has announced the opening of The Lya Segall Ovarian Cancer Institute at Mercy, the first center in Maryland specifically designed and dedicated solely for the diagnosis and treatment of ovarian cancer. [More]
CorMedix submits IND application to FDA for Neutrolin

CorMedix submits IND application to FDA for Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that an Investigational New Drug application (IND) for Neutrolin was submitted to the United States Food and Drug Administration on Wednesday, September 24, 2014. [More]
Study identifies potential way to improve treatment for chemo-resistant ovarian cancer

Study identifies potential way to improve treatment for chemo-resistant ovarian cancer

Ovarian cancer is the most deadly gynecological cancer, claiming the lives of more than 50% of women who are diagnosed with the disease. [More]

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

A review of patients with advanced pulmonary carcinoid tumours shows that they can be responsive to chemotherapy. [More]